The Comprehensive in vitro Proarrhythmia Assay (CiPA) is a Safety Pharmacology paradigm for discovering electrophysiological mechanisms, led by the US FDA. The purpose is to improve preclinical cardiac safety evaluation and lower unwanted drug attrition. The CIPA assay is used to measure the electrophysiology of human heart arrhythmias. This is a non-invasive test that is […]
